Psychedelics drugs such as psilocybin and MDMA are on the cusp of becoming mainstream treatment options in psychiatry, according to the New York Times. After years of demonization and criminalization, such drugs are attracting attention from researchers, universities, therapists and lawmakers—and of course Wall Street—which sees a potential booming market. This will have profound implications for psychiatry, as classic psychedelics including LSD have shown early potential to treat conditions such as depression and PTSD. But amid the drive to commercialize and legalize the drugs, many worry that more research is needed on possible side effects, as well as stringent oversight and regulations if such treatments become more available. Meanwhile, the Wall Street Journalreports that millions of dollars are flowing to “platoons” of cannabis lobbyists, banks and new marijuana trade organizations in an attempt to shape the future of the industry. As more states legalize pot—there are now 17, plus the District of Columbia—and Congress considers loosening federal-level laws and banking restrictions, the lobbyists are influencing the ground rules for this emerging market. They include corporations, union advocates, personal-use supporters and social-justice activists, reflecting the industry’s widening base even as some of the groups have differing goals. And finally, conservative states are lining up to legalize medical marijuana. Such bills are pending in Republican-controlled legislatures in North Carolina, Alabama and Kansas for the first time, even though clinical studies have yet to establish that medical pot is indeed effective for many conditions supporters claim it helps.